Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail

• ClinicalTrials.gov Identifier: NCT00679523
• Recruitment Status: Completed
• First Posted: May 19, 2008
• Last Update Posted: November 14, 2018
• Sponsor: Pfizer
• Information provided by: Pfizer

Tracking Information

• First Submitted Date: May 15, 2008
• First Posted Date: May 19, 2008
• Last Update Posted Date: November 14, 2018
• Study Start Date: November 2005
• Actual Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: May 16, 2008): A calculated endpoint of treatment response at Day 180 comprised of the ISGA, clear nail growth and fungal culture results [ Time Frame: Day 180 ]
• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures (submitted: May 16, 2008): Mycological and clinical response of "complete responders", "partial responders", and "non-responder". [ Time Frame: Days 180 ]
• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
• Official Title: An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail
• Brief Summary: The purpose of the study is to determine the safety and efficacy of 5.0% and 7.5% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.
• Detailed Description: The first group of 30 protocol-qualified subjects will be assigned to Treatment Group 1 and given 5% AN2690 Solution. Provided that there is adequate evidence of clinical safety after two weeks of dosing with 5% AN2690 Solution, a second group of 30 protocol-qualified subjects will be assigned to Treatment Group 2 and given 7.5% AN2690 Solution. A third group of 30 subjects will be enrolled and assigned the highest safe concentration of AN2690 evaluated in this study.
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Onychomycosis

Intervention

• Drug: AN2690 Solution, 5.0%
  Once daily application for 180 days
• Drug: AN2690 Solution, 7.5%
  Once daily application for 180 days

Study Arms

• Experimental: Group 1
  AN2690 Solution, 5.0%
  Intervention: Drug: AN2690 Solution, 5.0%
• Experimental: Group 2
  AN2690 Solution, 7.5%
  Intervention: Drug: AN2690 Solution, 7.5%

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: May 16, 2008): 60
• Original Actual Enrollment: Same as current
• Actual Study Completion Date: February 2007
• Actual Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Witnessed, signed informed consent approved by Ethics Committee
2. Male or female subjects of any race at least 18 years of age but not older than 65 years of age at the time of screening
3. Subjects with a diagnosis of onychomycosis of at least one great toenail and with a positive KOH wet mount from that nail
4. Onychomycosis involving 20-60% of the affected great toenail as determined by visual inspection after the nail has been trimmed
5. The combined thickness of the distal nail plate and the associated hyperkeratotic nail bed <3 mm
6. Affected great toenail to be treated is capable of re-growth as documented by history or recent observation of at least 2 mm of growth
7. Normal or not clinically significant screening safety labs

Exclusion Criteria:

1. Females of childbearing potential not using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study
2. Diabetes mellitus requiring treatment other than diet and exercise
3. Subjects with chronic moccasin type of T. pedis
4. Subjects with a history of having failed any previous topical antifungal therapy for their onychomycosis
5. Subjects unwilling to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study.

6. Subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications:

   • Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study): 4 weeks
   • Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks

7. Subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:

   • Corticosteroids (including intramuscular injections): 2 weeks
   • Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophytes: 24 weeks
   • Systemic immunomodulators: 4 weeks
8. Treatment of any type for cancer within the last 6 months
9. History of any significant internal disease
10. Subjects with a medical history of current or past psoriasis of the skin and/or nails
11. Concurrent lichen planus
12. Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
13. Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
14. AIDS or AIDS related complex
15. History of street drug or alcohol abuse
16. Any subject not able to meet the study attendance requirements
17. Subjects who have participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 65 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Mexico

Administrative Information

• NCT Number: NCT00679523
• Other Study ID Numbers: AN2690-ONYC-201 Cohort 1 and 2
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Karl Beutner, MD, PhD, Anacor Pharmaceuticals, Inc.
• Study Sponsor: Pfizer
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Pfizer
• Verification Date: November 2018